Valsartan Cancer Lawsuits
The Food and Drug Administration recently announced a voluntary recall of widely-prescribed blood pressure medications containing valsartan over cancer concerns.
Have you recently received a valsartan recall letter? If so, you aren’t alone. On July 13, 2018, the United States Food and Drug Administration (FDA) issued it’s largest ever class 1 recall due to the generic blood pressure medication valsartan being contaminated with the impurity N-Nitrosodimethylamine (NDMA). A well-known side effect of NDMA is cancer formation. 1 in 3 Americans suffers from hypertension, with valsartan being one of the primary drugs utilized to treat hypertension. As a result, approximately 2 million Americans have received recall letters from Humana regarding the FDA’s urgent recall of contaminated valsartan. Time will tell how many experiences the unfortunate side effects of contaminated valsartan.
Recently, batches of losartan and irbesartan have also tested positive for carcinogenic impurities. Losartan, irbesartan, and valsartan are in the same class of blood pressure medications (ARBs). The full extent of the valsartan contamination and how many other ARBs contain carcinogenic impurities is still unknown. The numerous regulatory investigations continue to uncover more carcinogenic impurities as legal actions mount. Several lawsuits alleging cancer development due to valsartan impurities have now been filed across the United States, along with numerous class action claims. On October 22, 2018, a motion was filed to consolidate all federal valsartan impurity lawsuits into the District of New Jersey in front of Judge Freda L. Wolfson. The Judicial Panel on Multidistrict Litigation (JPML) heard arguments to consolidate all claims on January 31, 2018, in Miami, Florida. On February 14, 2019, the JPML decided to consolidate all valsartan cases in the District of New Jersey in front of Judge Robert B. Kugler. The valsartan litigation is now known as MDL 2875 – In Re: Valsartan N-Nitrosodimethylamine (NDMA) Contamination Products Liability Litigation. Make sure to bookmark this page to stay up to date as the valsartan investigation continues and the litigation takes the form to hold those accountable for this catastrophe responsible.
Valsartan Side Effects
The full extent of the potential side effects and injuries due to impurities within valsartan are currently being investigated. The NDMA and other carcinogens within valsartan are rapidly absorbed in the upper part of the small intestine and carried to the liver in the portal blood supply. The liver can effectively metabolize and clear small amounts of NDMA, leaving very little to interact with other organs. Therefore, the liver is must susceptible organ to experience side effects from contaminated valsartan. The side effects of long-term exposure to valsartan are not currently well understood. Our valsartan attorneys are currently filing lawsuits for those who have experienced the following side effects or injuries:
- Stomach cancer
- Liver cancer
- Colorectal cancer
- Pancreatic cancer
- Esophageal Cancer
- Bowel cancer
- Liver failure
Which Medications Are Included in the Valsartan Recall?
- Valsartan and Valsartan Hydrochlorothiazide Tablets Impurity detected in the API is Nnitrosodimethylamine (NDMA)
Teva Pharmaceuticals USA
- Prinston Pharmaceutical Inc. dba Solco Healthcare LLC Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg Detection of a Trace Amount of Unexpected Impurity, N- nitrosodimethylamine (NDMA) Prinston Pharmaceutical Inc. dba Solco Healthcare LLC
- Major Pharmaceuticals Valsartan tablets, 80mg USP and 160 mg USP May contain the probable carcinogen Nnitrosodimethylamine (NDMA) Major Pharmaceuticals
How Dangerous is Valsartan Contaminated with NDMA?
Ingestion of N-Nitrosodimethylamine or NDMA poses a significant risk for cancer formation. In 2002, the World Health Organization (WHO) declared “NDMA has been consistently potently carcinogenic in all experimental species examined.” In fact, NDMA is considered so dangerous and carcinogenic that human trials are not even allowed, and therefore have never been performed! Even acute, single exposure studies in animals have demonstrated that NDMA causes liver (hepatotoxicity), kidney (tumors), and testes (necrosis of the seminiferous epithelium). Additionally, as the amount and/or the time of NDMA exposure increased in animals, so did the rates of tumor and cancer formation.
Hiring A Valsartan Lawsuit Attorney
The attorneys at Jones Brown Law are currently evaluating and investigating claims on behalf of patients who have been diagnosed with cancer as a potential side effect of ingesting a known human carcinogen. If you have been diagnosed with cancer or lost a loved after ingesting valsartan, please contact us immediately.
In many cases, filing a valsartan lawsuit is the only way to recover money that is lost from hospital expenses, lost wages, and for some – funeral costs. Others file lawsuits because they want to make a difference and prevent others from suffering through the same horrors as they have.
Contact Jones Brown Law
There are countless medications and devices on the market or that have recently been taken off of the market that has affected the lives of unknowing victims worldwide. The hardest part is getting this information out to these victims.
Our Jones Brown Law team has experience helping countless victims of defective drugs and devices. We understand each case is different, however, we will help you recover what you are entitled to and we understand what you are going through when you are dealing with a defective drug lawsuit or a defective medical device lawsuit. You can fill out our Defective Drug Evaluation HERE, to get your Valsartan Cancer Lawsuit started.